$NMR ACCE Score Jumps 13 Points to 78 — What's Driving It
Nomura Holdings ADR $NMR sees its ACCE composite score rise from 65 to 78. Growth at 100/100 and Momentum at 90/100 lead the move. Here's what the data shows.
The ACCE composite score for $NMR (Nomura Holdings Inc ADR) moved from 65 to 78, a delta of +13 points. That is a meaningful single-step move for any stock in our model, and the current score breakdown tells you where the conviction is concentrated.
Growth sits at a perfect 100/100. Momentum scores 90/100. Those two subscore readings are doing the heavy lifting, and the underlying data backs them up. Revenue grew 31.2% year-over-year, earnings grew 42.0% year-over-year, and the stock has returned 45.1% over the past twelve months. $NMR also beat earnings estimates in Q3 FY2026, though only by 0.3%, so the beat itself is modest — the scale of the underlying growth is what stands out.
Value scores 56/100 and Quality scores 64/100, both solidly in positive territory but not the story here. The trailing P/E sits at 11.8 and the forward P/E at 15.4, which suggests the market is pricing in continued earnings expansion. ROE is 11.2%, net margin is 17.3%, and earnings quality is rated strong — respectable figures for a large financial services firm.
Recibe el resumen semanal de ACCE
Rentabilidad de los índices, repaso de las selecciones y los mayores cambios de puntuación, cada domingo. Sin relleno.
The dividend yield of 3.4% adds an income component that can attract a different category of buyer, which may contribute to sustained demand in the shares.
What it means
A +13-point score move of this size typically reflects a broad improvement across multiple inputs rather than a single data point flipping. Here, the most plausible drivers are the Growth subscore reaching its ceiling at 100 and Momentum reinforcing that with a 90 reading — both consistent with the 42.0% earnings growth and 45.1% one-year price return in the data.
One note of caution worth flagging directly: our 6-model fair value estimate for $NMR is $6.56, which sits 32.0% below the current price of $9.65. The analyst consensus target of $10.31 points in the opposite direction. These two figures are in significant disagreement, and that gap is worth understanding before drawing conclusions about valuation. The ACCE score reflects momentum and growth strength — it does not override the fair value signal.
The Quality score of 64/100 and Value score of 56/100 suggest the model sees room for improvement on both fronts. Strong earnings growth and price momentum can coexist with valuation risk, and that appears to be the case here.
For current price and full model detail, see acceinvestments.com/stocks/NMR.
See the full picture, free
ACCE scores thousands of stocks across six valuation models, with fair value, conviction and the full thesis on every name. Start free, no card required.
